



- (51) **International Patent Classification:**
A61P 35/00 (2006.01) C12Q 1/6886 (2018.01)
- (21) **International Application Number:**
PCT/US2021/029435
- (22) **International Filing Date:**
27 April 2021 (27.04.2021)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/015,883 27 April 2020 (27.04.2020) US
- (71) **Applicant: VERASTEM, INC.** [US/US]; 117 Kendrick Street, Suite 500, Needham, Massachusetts 02494 (US).
- (72) **Inventors: PACHTER, Jonathan A.**; 2 Barley Lane, Wayland, Massachusetts 01778 (US). **PATERSON, Daniel**; 117 Kendrick Street, Suite 500, Needham, Massachusetts 02494 (US). **STUGLIK, Brian M.**; 1140 Twin Oak Court, Marco Island, Florida 34145 (US).

(74) **Agent: CHOI, Boyeon**; Goodwin Procter LLP, 100 Northem Avenue, IP DOCKETING DEPT./7TH FL, Boston, Massachusetts 02210 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: METHODS OF TREATING ABNORMAL CELL GROWTH




FIG. 1

(57) **Abstract:** The present invention relates to methods for treating abnormal cell growth (e.g., cancer) in a subject identified as having a KRAS mutation (e.g., KRAS G12X mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C)) comprising administering to the subject an effective amount of a MEK inhibitor (e.g., a dual RAF/MEK inhibitor) alone or in combination with an additional agent.

WO 2021/222278 A1

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*

METHODS OF TREATING ABNORMAL CELL GROWTH

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Patent Application No. 63/015,883 filed on April 27, 2020, the entire content of which is incorporated herein by reference.

BACKGROUND

Kirsten Rat Sarcoma 2 Viral Oncogene Homolog (KRAS) is a small GTPase and a member of the Ras family of oncogenes. KRAS serves as a molecular switch cycling between inactive (GDP-bound) and active (GTP-bound) states to transduce upstream cellular signals received from multiple tyrosine kinases to downstream effectors to regulate a wide variety of processes, including cellular proliferation (e.g., see Alamgeer et al., (2013) *Current Opin. Pharmacol.* 13:394-401). KRAS gene mutations are found in cancer, for example, pancreatic cancer, lung adenocarcinoma, colorectal cancer, gall bladder cancer, thyroid cancer, and bile duct cancer (Kodaz et al., EJMO 2017).

Components of the RAS/RAF/MEK/ERK signal transduction pathway represent opportunities for the treatment of abnormal cell growth, e.g., cancer. Selective inhibitors of certain components of the RAS/RAF/MEK/ERK signal transduction pathway, such as RAS, RAF, MEK, and ERK, are useful in the treatment of abnormal cell growth, in particular cancer, in mammals.

Due to the severity and breadth of diseases and disorders associated with abnormal cell growth (e.g., cancer), there is a need for effective therapeutic means and methods for treatment. Compounds, compound combinations, compositions, and methods described herein are directed toward this end.

SUMMARY

The present disclosure provides, in part, methods of treating abnormal cell growth (e.g., cancer) in a subject in need thereof. Methods provided herein are contemplated as being useful for treating a subject identified as having a KRAS mutation. For example, a KRAS mutation may be at codon 12 of the KRAS gene, for instance, as a single point substitution mutation at codon 12 (i.e., KRAS G12X mutation). Exemplary KRAS G12X mutations include, but are not limited to, KRAS G12V, KRAS G12D, KRAS G12A, KRAS

G12R, KRAS G12S, or KRAS G12C. The methods comprise treating the subject by administering an effective amount of a MEK inhibitor described herein (e.g., a dual RAF/MEK inhibitor) alone or in combination with an additional agent described herein. Alternatively, the methods may comprise treating the subject by administering a pan-RAF inhibitor alone or in combination with an additional agent described herein.

In an aspect, provided herein is a method of treating a cancer in a subject identified as having a KRAS G12V mutation, the method comprising administering to the subject an effective amount of a MEK inhibitor (e.g., a dual RAF/MEK inhibitor), thereby treating the subject.

In an aspect, provided herein is a method of treating a cancer in a subject identified as having a KRAS G12D mutation, the method comprising administering to the subject an effective amount of a MEK inhibitor (e.g., a dual RAF/MEK inhibitor), thereby treating the subject.

In an aspect, provided herein is a method of treating a cancer characterized as having a KRAS G12V mutation in a subject in need thereof, method comprising administering to the subject an effective amount of a MEK inhibitor (e.g., a dual RAF/MEK inhibitor), thereby treating the subject.

In an aspect, provided herein is a method of treating a cancer characterized as having a KRAS G12D mutation in a subject in need thereof, method comprising administering to the subject an effective amount of a MEK inhibitor (e.g., a dual RAF/MEK inhibitor), thereby treating the subject.

In some embodiments, the MEK inhibitor is selected from the group consisting of trametinib, cobimetinib, binimetinib, selumetinib, PD-325901, CI-1040, VS-6766, MEK162, AZD8330, GDC-0623, refametinib, pimasertib, WX-554, HL-085, CH4987655, TAK-733, CInQ-03, G-573, PD184161, PD318088, PD98059, RO5068760, U0126, and SL327, or a pharmaceutically acceptable salt thereof.

In some embodiments, the MEK inhibitor is a dual RAF/MEK inhibitor.

In some embodiments, the MEK inhibitor (e.g., a dual RAF/MEK inhibitor) is VS-6766 or a pharmaceutically acceptable salt thereof.

In some embodiments, the MEK inhibitor (e.g., VS-6766 or a pharmaceutically acceptable salt thereof) is dosed twice a week.

In some embodiments, the MEK inhibitor (e.g., VS-6766 or a pharmaceutically acceptable salt thereof) is dosed at about 0.5 mg to about 10 mg (e.g., about 4 mg or about 3.2 mg).

In some embodiments, the MEK inhibitor (e.g., VS-6766 or a pharmaceutically acceptable salt thereof) is dosed cyclically for three weeks on and then one week off.

In some embodiments, the MEK inhibitor (e.g., VS-6766 or a pharmaceutically acceptable salt thereof) is administered in combination with an additional agent. In some
5 embodiments, the additional agent is administered prior to the MEK inhibitor. In some
embodiments, the additional agent is administered concurrently with the MEK inhibitor. In
some embodiments, the additional agent is administered subsequent to the MEK inhibitor.

In some embodiments, the additional agent is a FAK inhibitor. In some embodiments,
the FAK inhibitor is selected from the group consisting of defactinib, TAE226, BI-853520
10 (IN10018), GSK2256098, PF-03814735, BI-4464, VS-4718, and APG-2449, or a
pharmaceutically acceptable salt thereof. In some embodiments, the FAK inhibitor is
defactinib or a pharmaceutically acceptable salt thereof.

In some embodiments, the FAK inhibitor (e.g., defactinib or a pharmaceutically
acceptable salt thereof) is dosed once daily. In some embodiments, the FAK inhibitor (e.g.,
15 defactinib or a pharmaceutically acceptable salt thereof) is dosed twice daily.

In some embodiments, the FAK inhibitor (e.g., defactinib or a pharmaceutically
acceptable salt thereof) is dosed at about 100 mg to about 1000 mg. In some embodiments,
the FAK inhibitor (e.g., defactinib or a pharmaceutically acceptable salt thereof) is dosed at
about 200 mg to about 400 mg (e.g., 200 mg or 400 mg).

In some embodiments, the FAK inhibitor (e.g., defactinib or a pharmaceutically
20 acceptable salt thereof) is dosed daily at about 400 mg to about 800 mg. For example, the
FAK inhibitor (e.g., defactinib or a pharmaceutically acceptable salt thereof) may be dosed
twice daily at about 200 mg to about 400 mg (e.g., about 200 mg or about 400 mg twice
daily).

In some embodiments, the MEK inhibitor (e.g., VS-6766 or a pharmaceutically
25 acceptable salt thereof) is dosed as a cycle, wherein the cycle comprises administering the
MEK inhibitor for three weeks and then not administering the MEK inhibitor for one week.

In some embodiments, the MEK inhibitor (e.g., VS-6766 or a pharmaceutically
acceptable salt thereof) and the FAK inhibitor (e.g., defactinib or a pharmaceutically
30 acceptable salt thereof) are dosed as a cycle, wherein the cycle comprises administering the
MEK inhibitor and the FAK inhibitor for three weeks and then not administering the MEK
inhibitor and the FAK inhibitor for one week.

In some embodiments, the MEK inhibitor (e.g., VS-6766 or a pharmaceutically
acceptable salt thereof) and the FAK inhibitor (e.g., defactinib or a pharmaceutically

acceptable salt thereof) are independently dosed as a cycle. In some embodiments, the MEK inhibitor (e.g., VS-6766 or a pharmaceutically acceptable salt thereof) and the FAK inhibitor (e.g., defactinib or a pharmaceutically acceptable salt thereof) are simultaneously dosed as a cycle.

5 In some embodiments, the MEK inhibitor (e.g., VS-6766 or a pharmaceutically acceptable salt thereof) is dosed at about 0.5 mg to about 10 mg and the FAK inhibitor (e.g., defactinib or a pharmaceutically acceptable salt thereof) is dosed at about 200 mg to about 400 mg. In some embodiments, the MEK inhibitor (e.g., VS-6766 or a pharmaceutically acceptable salt thereof) is dosed at about 4 mg twice a week and the FAK inhibitor (e.g.,
10 defactinib or a pharmaceutically acceptable salt thereof) is dosed at about 200 mg twice daily.

In some embodiments, the MEK inhibitor (e.g., VS-6766 or a pharmaceutically acceptable salt thereof) is dosed at about 3.2 mg twice a week and the FAK inhibitor (e.g., defactinib or a pharmaceutically acceptable salt thereof) is dosed at about 200 mg twice daily.

15 In some embodiments, the MEK inhibitor (e.g., VS-6766 or a pharmaceutically acceptable salt thereof) is dosed at about 4 mg twice a week and the FAK inhibitor (e.g., defactinib or a pharmaceutically acceptable salt thereof) is dosed at about 400 mg twice daily.

In some embodiments, the MEK inhibitor (e.g., VS-6766 or a pharmaceutically acceptable salt thereof) is dosed at about 3.2 mg twice a week and the FAK inhibitor (e.g., defactinib or a pharmaceutically acceptable salt thereof) is dosed at about 400 mg twice daily.

20 In some embodiments, the cancer is ovarian cancer, non-small cell lung cancer (e.g., NSCLC adenocarcinoma)), uterine endometrioid carcinoma, pancreatic adenocarcinoma, colorectal adenocarcinoma, or lung adenocarcinoma. In some embodiments, the cancer is NSCLC (e.g., KRAS G12V mutant NSCLC).

In another aspect, provided herein is a method of detecting presence of a KRAS gene
25 mutation associated with a subject having a cancer, the method comprising:

- (a) obtaining a biological sample from the subject; and
- (b) performing an assay that screens for mutation in the sample.

In another aspect, provided herein is a method of identifying a subject having a cancer with a KRAS gene mutation, the method comprising:

- 30
- (a) obtaining a biological sample from the subject; and
 - (b) performing an assay that screen for mutation in the sample.

In some embodiments, the methods further comprise administering to the subject identified as having a cancer with a KRAS mutation (e.g., KRAS G12X mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C)) an

effective amount of a MEK inhibitor described herein (e.g., a dual RAF/MEK inhibitor) alone or in combination with an additional agent (e.g., a FAK inhibitor).

In alternative embodiments, the methods may further comprise administering to the subject identified as having a cancer with a KRAS mutation (e.g., KRAS G12X mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C)) an effective amount of a pan-RAF inhibitor alone or in combination with an additional agent (e.g., a FAK inhibitor).

In some embodiments, the KRAS gene mutation is G12A, G12C, G12D, G12R, G12S, G12V or G13D. In some embodiments, the KRAS gene mutation is G12V. In some embodiments, the cancer is NSCLC.

Other objects and advantages will become apparent to those skilled in the art from a consideration of the ensuing Detailed Description, Examples, and Claims.

BRIEF DESCRIPTION OF THE DRAWINGS

- 15 **FIG. 1** shows exemplary best response by RECIST in KRAS G12V NSCLC for the monotherapy of VS-6766 and combination therapy of VS-6766 and defactinib.
- FIG. 2** shows the time on treatment for KRAS G12V NSCLC.
- FIG. 3** shows exemplary best response by RECIST in KRAS G12V tumors (endometrial, NSCLC, and ovarian) for the monotherapy of VS-6766 and combination therapy of VS-6766 and defactinib.
- 20 **FIG. 4** shows the time on treatment for KRAS G12V tumors (endometrial, NSCLC, and ovarian).

DETAILED DESCRIPTION

25 As generally described herein, the present disclosure provides methods that are useful for treating abnormal cell growth (e.g., cancer) in a subject in need thereof. Contemplated subjects in need of treatment of cancer may be identified as having a KRAS mutation (e.g., KRAS G12X mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C)).

30

Definitions

"About" and "approximately" shall generally mean an acceptable degree of error for the quantity measured given the nature or precision of the measurements. Exemplary degrees of error are within 20 percent (%), typically, within 10%, and more typically, within 5% of a given value or range of values.

As used herein, "pharmaceutically acceptable salt" refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, Berge *et al.*, describes pharmaceutically acceptable salts in detail in *J. Pharmaceutical Sciences* (1977) 66:1–19. Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxyethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like. Pharmaceutically acceptable salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and $N^+(C_{1-4}alkyl)_4$ salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate, and aryl sulfonate.

As used herein, “pharmaceutically acceptable carrier” refers to a non-toxic carrier, adjuvant, or vehicle that does not destroy the pharmacological activity of the compound with which it is formulated. Pharmaceutically acceptable carriers, adjuvants or vehicles that may be used in the compositions described herein include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.

As used herein, a “subject” to which administration is contemplated includes, but is not limited to, humans (i.e., a male or female of any age group, e.g., a pediatric subject (e.g., infant, child, adolescent) or adult subject (e.g., young adult, middle-aged adult or senior adult)) and/or a non-human animal, e.g., a mammal such as primates (e.g., cynomolgus monkeys, rhesus monkeys), cattle, pigs, horses, sheep, goats, rodents, cats, and/or dogs. In certain embodiments, the subject is a human. In certain embodiments, the subject is a non-human animal. The terms “human,” “patient,” and “subject” are used interchangeably herein.

Disease, disorder, and condition are used interchangeably herein.

As used herein, and unless otherwise specified, the terms “treat,” “treating” and “treatment” contemplate an action that occurs while a subject is suffering from the specified disease, disorder or condition, which reduces the severity of the disease, disorder or condition, or retards or slows the progression of the disease, disorder or condition (also “therapeutic treatment”).

In general, the “effective amount” of a compound refers to an amount sufficient to elicit the desired biological response. As will be appreciated by those of ordinary skill in this art, the effective amount of a compound of the invention may vary depending on such factors as the desired biological endpoint, the pharmacokinetics of the compound, the disease being treated, the mode of administration, and the age, weight, health, and condition of the subject.

As used herein, and unless otherwise specified, a “therapeutically effective amount” of a compound is an amount sufficient to provide a therapeutic benefit in the treatment of a disease, disorder or condition, or to delay or minimize one or more symptoms associated with the disease, disorder or condition. A therapeutically effective amount of a compound means an amount of therapeutic agent, alone or in combination with other therapies, which provides

a therapeutic benefit in the treatment of the disease, disorder or condition. The term “therapeutically effective amount” can encompass an amount that improves overall therapy, reduces or avoids symptoms or causes of disease or condition, or enhances the therapeutic efficacy of another therapeutic agent.

5 As used herein, “prophylactic treatment” contemplates an action that occurs before a subject begins to suffer from the specified disease, disorder or condition.

As used herein, and unless otherwise specified, a “prophylactically effective amount” of a compound is an amount sufficient to prevent a disease, disorder or condition, or one or more symptoms associated with the disease, disorder or condition, or prevent its recurrence.

10 A prophylactically effective amount of a compound means an amount of a therapeutic agent, alone or in combination with other agents, which provides a prophylactic benefit in the prevention of the disease, disorder or condition. The term “prophylactically effective amount” can encompass an amount that improves overall prophylaxis or enhances the prophylactic efficacy of another prophylactic agent.

15 The term, "oral dosage form," as used herein, refers to a composition or medium used to administer an agent to a subject. Typically, an oral dosage form is administered via the mouth, however, "oral dosage form" is intended to cover any substance which is administered to a subject and is absorbed across a membrane, e.g., a mucosal membrane, of the gastrointestinal tract, including, e.g., the mouth, esophagus, stomach, small intestine, large

20 intestine, and colon. For example, "oral dosage form" covers a solution which is administered through a feeding tube into the stomach.

A "KRAS mutation" is a mutation of the KRAS gene (i.e., a nucleic acid mutation) or Kras protein (i.e., an amino acid mutation) that results in aberrant Kras protein function associated with increased and/or constitutive activity by favoring the active GTP-bound state

25 of the Kras protein. The mutation may be at conserved sites that favor GTP binding and constitutively active Kras protein. In some instances, the mutation is at one or more of codons 12, 13, and 16 of the KRAS gene. For example, a KRAS mutation may be at codon 12 of the KRAS gene, for instance, as a single point substitution mutation at codon 12 (i.e., KRAS G12X mutation) (e.g., a KRAS G12V mutation arises from a single nucleotide change

30 (c.35G>T) and results in an amino acid substitution of the glycine (G) at position 12 by a valine (V)). Exemplary KRAS G12X mutations include, but are not limited to, KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C.

Methods of Treatment

Methods disclosed herein contemplate treating a subject identified as having a KRAS mutation (e.g., KRAS G12X mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C)) by administering to the subject an effective amount of a MEK inhibitor (e.g., a dual RAF/MEK inhibitor) alone or in combination with an additional agent (e.g., a FAK inhibitor).

In an aspect, provided herein is a method of treating a cancer in a subject identified as having a KRAS G12V mutation, the method comprising administering to the subject an effective amount of a MEK inhibitor, thereby treating the subject.

In an aspect, provided herein is a method of treating a cancer in a subject identified as having a KRAS G12D mutation, the method comprising administering to the subject an effective amount of a MEK inhibitor, thereby treating the subject.

In an aspect, provided herein is a method of treating a cancer characterized as having a KRAS G12V mutation in a subject in need thereof, method comprising administering to the subject an effective amount of a MEK inhibitor, thereby treating the subject.

In an aspect, provided herein is a method of treating a cancer characterized as having a KRAS G12D mutation in a subject in need thereof, method comprising administering to the subject an effective amount of a MEK inhibitor, thereby treating the subject.

In an aspect, provided herein is a method of treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of a MEK inhibitor, wherein the subject has previously been identified as having a KRAS mutation (e.g., KRAS G12X mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C)).


In an aspect, provided herein is a method of treating cancer in a subject in need thereof, comprising selecting a subject with cancer having a KRAS mutation (e.g., KRAS G12X mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C)) in a tumor of the subject; and treating the subject with an effective amount of a MEK inhibitor.

MEK Inhibitors

A MEK inhibitor can be a small molecule or biologic inhibitor of the mitogen-activated protein kinase (MAPK) enzymes MEK1 and/or MEK2 (e.g., MAPK/ERK pathway).


Examples of MEK inhibitors include, but are not limited to:

CH5126766 (also known as RO5126766 or CKI27; also described herein as VS-6766) having the following structure:



;


Trametinib (also known as Mekinst, GSK1120212) having the following structure:



5


;

Cobimetinib (also known as GDC-0973, XL518) having the following structure:




;

Binimetinib having the following structure:




10 CI-1040 (also known as PD184352) having the following structure:




;


PD-325901 having the following structure:



Selumetinib (also known as AZD6244) having the following structure:




MEK162 having the following structure:




5


AZD8330 having the following structure:




TAK-733 having the following structure:




10 GDC-0623 having the following structure:



Refametinib (also known as RDEA119; BAY 869766) having the following structure:




Pimasertib (also known as AS4987655) having the following structure:




5


RO4987655 (also known as CH4987655) having the following structure:




CInQ-03 having the following structure:




10 G-573 having the following structure:




PD184161 having the following structure:




PD318088 having the following structure:




PD98059 having the following structure:




RO5068760 having the following structure:



SL327 having the following structure:



10 U0126 having the following structure:



WX-554 (Wilex); and HL-085 (Shanghai Kechow Pharma).

In some embodiments, the MEK inhibitor is selected from the group consisting of trametinib, cobimetinib, binimetinib, selumetinib, PD-325901, CI-1040, VS-6766, MEK162, AZD8330, GDC-0623, refametinib, pimasertib, WX-554, HL-085, CH4987655, TAK-733, CInQ-03, G-573, PD184161, PD318088, PD98059, RO5068760, U0126, and SL327, or a pharmaceutically acceptable salt thereof.

In some embodiments, the MEK inhibitor is dosed at least once a week (e.g., once a week, twice a week, three times a week, four times a week, five times a week, or six times a week). In some embodiments, the MEK inhibitor is dosed once a week. In some embodiments, the MEK inhibitor is dosed twice a week. In some embodiments, the MEK inhibitor is dosed once daily. In some embodiments, the MEK inhibitor is dosed twice daily. In some embodiments, the MEK inhibitor is dosed for at least three weeks. In some embodiments, the MEK inhibitor is dosed cyclically (e.g., a cycle comprising administering the MEK inhibitor for three weeks and then not administering the MEK inhibitor for one week).

In some embodiments, the MEK inhibitor is dosed at about 0.1 mg to about 100 mg, e.g., about 0.1 mg to about 50 mg, about 0.1 mg to about 10 mg, about 0.1 mg to about 5 mg, about 0.1 mg to about 4 mg, about 0.1 mg to about 3 mg, about 0.1 mg to about 2 mg, about 0.1 mg to about 1 mg, about 1 mg to about 10 mg, about 1 mg to about 20 mg, about 1 mg to about 40 mg, about 1 mg to about 60 mg, about 1 mg to about 80 mg, about 1 mg to about 100 mg, about 10 mg to about 100 mg, about 20 mg to about 100 mg, about 40 mg to about 100 mg, about 60 mg to about 100 mg, or about 80 mg to about 100 mg. In some embodiments, the MEK inhibitor is dosed at about 0.5 mg to about 10 mg. In some embodiments, the MEK inhibitor is dosed at about 0.1 mg, 0.2 mg, 0.5 mg, 1 mg, 1.5 mg, 3 mg, 4 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, or 100 mg. In some embodiments, the MEK inhibitor is dosed at about 4 mg. In some embodiments, the MEK inhibitor is dosed at about 3.2 mg. In some embodiments, the MEK inhibitor is administered orally.

In some embodiments, the MEK inhibitor is a dual RAF/MEK inhibitor. In some embodiments, the MEK inhibitor is VS-6766 or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutically acceptable salt of VS-6766 is a potassium salt of VS-6766. In some embodiments, the dual RAF/MEK inhibitor is dosed at least once a week (e.g., once a week, twice a week, three times a week, four times a week, five times a week, or six times a week). In some embodiments, the dual RAF/MEK inhibitor is dosed once a week. In some embodiments, the dual RAF/MEK inhibitor is dosed twice a week. In some embodiments, the dual RAF/MEK inhibitor is dosed once daily. In some embodiments, the dual RAF/MEK inhibitor is dosed twice daily. In some embodiments, the dual RAF/MEK inhibitor is dosed at about 0.1 mg to about 100 mg, e.g., about 0.1 mg to about 50 mg, about 0.1 mg to about 10 mg, about 0.1 mg to about 5 mg, about 0.1 mg to about 4 mg, about 0.1 mg to about 3 mg, about 0.1 mg to about 2 mg, about 0.1 mg to about 1 mg, about 1 mg to about 10 mg, about 1 mg to about 20 mg, about 1 mg to about 40 mg, about 1 mg to about 60 mg, about 1 mg to about 80 mg, about 1 mg to about 100 mg, about 10 mg to about 100 mg, about 20 mg to about 100 mg, about 40 mg to about 100 mg, about 60 mg to about 100 mg, or about 80 mg to about 100 mg. In some embodiments, the MEK inhibitor is dosed at about 0.5 mg to about 10 mg. In some embodiments, the dual RAF/MEK inhibitor is dosed at about 0.1 mg, 0.2 mg, 0.5 mg, 1 mg, 1.5 mg, 3 mg, 4 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, or 100 mg. In some embodiments, dual RAF/MEK inhibitor is dosed at about 4 mg. In some embodiments, the dual RAF/MEK inhibitor is dosed at about 3.2 mg. In some embodiments, the dual RAF/MEK inhibitor is administered orally.

In some embodiments, the MEK inhibitor (e.g., a dual RAF/MEK inhibitor (e.g., VS-6766 or a pharmaceutically acceptable salt thereof)) is dosed cyclically (e.g., as a cycle comprising administering the MEK inhibitor for three weeks and then not administering the MEK inhibitor for one week). In some embodiments, the MEK inhibitor (e.g., a dual RAF/MEK inhibitor (e.g., VS-6766 or a pharmaceutically acceptable salt thereof)) is dosed twice a week. In some embodiments, the MEK inhibitor (e.g., a dual RAF/MEK inhibitor (e.g., VS-6766 or a pharmaceutically acceptable salt thereof)) is dosed at about 0.5 mg to about 10 mg (e.g., about 4 mg or about 3.2 mg).

Alternatively, the methods may comprise treating the subject identified as having a KRAS mutation (e.g., KRAS G12X mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C)) by administering an effective amount of a pan-RAF inhibitor alone or in combination with an additional agent described herein.

In an aspect, provided herein is a method of treating a cancer in a subject identified as having a KRAS G12V mutation, the method comprising administering to the subject an effective amount of a pan-RAF inhibitor, thereby treating the subject.

In another aspect, provided herein is a method of treating a cancer in a subject identified as having a KRAS G12D mutation, the method comprising administering to the subject an effective amount of a pan-RAF inhibitor, thereby treating the subject.

Diseases and Disorders

Methods provided herein are contemplated as being useful for the treatment of a cancer characterized as having a KRAS mutation (e.g., KRAS G12X mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C)). For example, the cancer may include, but is not limited to, ovarian cancer, non-small cell lung cancer (e.g., NSCLC adenocarcinoma), uterine endometrioid carcinoma, pancreatic adenocarcinoma, colorectal adenocarcinoma, or lung adenocarcinoma. In some embodiments, the cancer is NSCLC (e.g., KRAS G12V mutant NSCLC).

Abnormal Cell Growth

Abnormal cell growth, as used herein and unless otherwise indicated, refers to cell growth that is independent of normal regulatory mechanisms (e.g., loss of contact inhibition). This includes the abnormal growth of: (1) tumor cells (tumors) that proliferate, for example, by expressing a mutated tyrosine kinase or overexpression of a receptor tyrosine kinase; (2) benign and malignant cells of other proliferative diseases, for example, in which aberrant tyrosine kinase activation occurs; (3) any tumors that proliferate, for example, by receptor tyrosine kinases; (4) any tumors that proliferate, for example, by aberrant serine/threonine kinase activation; and (5) benign and malignant cells of other proliferative diseases, for example, in which aberrant serine/threonine kinase activation occurs. Abnormal cell growth can refer to cell growth in epithelial (e.g., carcinomas, adenocarcinomas); mesenchymal (e.g., sarcomas (e.g. leiomyosarcoma, Ewing's sarcoma)); hematopoietic (e.g., lymphomas, leukemias, myelodysplasias (e.g., pre-malignant)); or other (e.g., melanoma, mesothelioma, and other tumors of unknown origin) cell.

Neoplastic Disorders

Abnormal cell growth can refer to a neoplastic disorder. A "neoplastic disorder" is a disease or disorder characterized by cells that have the capacity for autonomous growth or replication, e.g., an abnormal state or condition characterized by proliferative cell growth. An

abnormal mass of tissue as a result of abnormal cell growth or division, or a "neoplasm," can be benign, pre-malignant (carcinoma in situ) or malignant (cancer).

Exemplary neoplastic disorders include: carcinoma, sarcoma, metastatic disorders (e.g., tumors arising from prostate, colon, lung, breast and liver origin), hematopoietic
5 neoplastic disorders, e.g., leukemias, metastatic tumors. Treatment with the compound may be in an amount effective to ameliorate at least one symptom of the neoplastic disorder, e.g., reduced cell proliferation, reduced tumor mass, etc.

Cancer

The inventive methods of the present invention may be useful in the prevention and
10 treatment of cancer, including for example, solid tumors, soft tissue tumors, and metastases thereof. The disclosed methods are also useful in treating non-solid cancers. Exemplary solid tumors include malignancies (e.g., sarcomas, adenocarcinomas, and carcinomas) of the various organ systems, such as those of lung, breast, lymphoid, gastrointestinal (e.g., colon), and genitourinary (e.g., renal, urothelial, or testicular tumors) tracts, pharynx, prostate, and
15 ovary. Exemplary adenocarcinomas include colorectal cancers, renal-cell carcinoma, liver cancer (e.g., Hepatocellular carcinoma), non-small cell carcinoma of the lung, pancreatic (e.g., metastatic pancreatic adenocarcinoma) and cancer of the small intestine.

The cancer can include mesothelioma; neurofibromatosis; e.g., neurofibromatosis type 2, neurofibromatosis type 1; renal cancer; lung cancer, non-small cell lung cancer; liver
20 cancer; thyroid cancer; ovarian; breast cancer; a nervous system tumor; schwannoma; meningioma; schwannomatosis; neuroma acoustic; adenoid cystic carcinoma; ependymoma; ependymal tumors, or any other tumor which exhibits decreased merlin expression and/or mutation, and/or deletion and/or promotor hypermethylation of the NF-2 gene.

The cancer can include cancers characterized as comprising cancer stem cells, cancer
25 associated mesenchymal cells, or tumor initiating cancer cells. The cancer can include cancers that have been characterized as being enriched with cancer stem cells, cancer associated mesenchymal cells, or tumor initiating cancer cells (e.g., a tumor enriched with cells that have undergone an epithelial-to-mesenchymal transition or a metastatic tumor).

The cancer can be a primary tumor, i.e., located at the anatomical site of tumor
30 growth initiation. The cancer can also be metastatic, i.e., appearing at least a second anatomical site other than the anatomical site of tumor growth initiation. The cancer can be a recurrent cancer, i.e., cancer that returns following treatment, and after a period of time in which the cancer was undetectable. The recurrent cancer can be anatomically located locally to the original tumor, e.g., anatomically near the original tumor; regionally to the original

tumor, e.g., in a lymph node located near the original tumor; or distantly to the original tumor, e.g., anatomically in a region remote from the original tumor.

The cancer can also include for example, but is not limited to, epithelial cancers, breast, lung, pancreatic, colorectal (e.g., metastatic colorectal, e.g., metastatic KRAS mutated), prostate, head and neck, melanoma (e.g., NRAS mutated locally advanced or metastatic malignant cutaneous melanoma), acute myelogenous leukemia, and glioblastoma. Exemplary breast cancers include triple negative breast cancer, basal-like breast cancer, claudin-low breast cancer, invasive, inflammatory, metaplastic, and advanced HER-2 positive or ER-positive cancers resistant to therapy.

The cancer can also include lung adenocarcinoma, colorectal cancer, uterine endometrioid carcinoma, bladder urothelial carcinoma, breast invasive lobular carcinoma, cervical squamous cell carcinoma, cutaneous melanoma, endocervical adenocarcinoma, hepatocellular carcinoma, pancreatic adenocarcinoma, biphasic type pleural mesothelioma, renal clear cell carcinoma, renal clear cell carcinoma, stomach adenocarcinoma, tubular stomach adenocarcinoma, uterine carcinosarcoma, or uterine malignant mixed Mullerian tumor.

Other cancers include but are not limited to, uveal melanoma, brain, abdominal, esophagus, gastrointestinal, glioma, liver, tongue, neuroblastoma, osteosarcoma, ovarian, retinoblastoma, Wilm's tumor, multiple myeloma, skin, lymphoma, blood and bone marrow cancers (e.g., advanced hematological malignancies, leukemia, e.g., acute myeloid leukemia (e.g., primary or secondary), acute lymphoblastic leukemia, acute lymphocytic leukemia, T cell leukemia, hematological malignancies, advanced myeloproliferative disorders, myelodysplastic syndrome, relapsed or refractory multiple myeloma, advanced myeloproliferative disorders), retinal, bladder, cervical, kidney, endometrial, meningioma, lymphoma, skin, uterine, lung, non small cell lung, nasopharyngeal carcinoma, neuroblastoma, solid tumor, hematologic malignancy, squamous cell carcinoma, testicular, thyroid, mesothelioma, brain vulval, sarcoma, intestine, oral, endocrine, salivary, spermatocyte seminoma, sporadic medullary thyroid carcinoma, non-proliferating testes cells, cancers related to malignant mast cells, non-Hodgkin's lymphoma, and diffuse large B cell lymphoma.

In some embodiments, the tumor is a solid tumor. In some embodiments, the solid tumor is locally advanced or metastatic, in some embodiments, the solid tumor is refractory (e.g., resistant) after standard therapy.

Methods described herein can reduce, ameliorate or altogether eliminate the disorder, and/or its associated symptoms, to keep it from becoming worse, to slow the rate of progression, or to minimize the rate of recurrence of the disorder once it has been initially eliminated (i.e., to avoid a relapse). A suitable dose and therapeutic regimen may vary
5 depending upon the specific compounds, combinations, and/or pharmaceutical compositions used and the mode of delivery of the compounds, combinations, and/or pharmaceutical compositions. In some embodiments, the method increases the average length of survival, increases the average length of progression-free survival, and/or reduces the rate of recurrence, of subjects treated with the combinations described herein in a statistically
10 significant manner.

In some embodiments, the cancer is lung cancer (e.g., non-small cell lung cancer (NSCLC), e.g., KRAS mutant NSCLC (e.g., KRAS G12V mutant NSCLC); metastatic cancer), bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer (e.g., unresectable low-grade ovarian,
15 advanced or metastatic ovarian cancer), rectal cancer, cancer of the anal region, stomach cancer, colon cancer, breast cancer (e.g., triple-negative breast cancer (e.g., breast cancer which does not express the genes for the estrogen receptor, progesterone receptor, and Her2/neu)), uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease,
20 cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, chronic or acute leukemia, lymphocytic lymphomas, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, neoplasms of the central nervous system
25 (CNS), primary CNS lymphoma, spinal axis tumors, brain stem glioma, pituitary adenoma, mesothelioma (e.g., malignant pleural mesothelioma, e.g., surgical resectable malignant pleural mesothelioma) or a combination of one or more of the foregoing cancers. In some embodiments, the cancer is metastatic. In some embodiments, the abnormal cell growth is locally recurring (e.g., the subject has a locally recurrent disease, e.g., cancer).

30


Additional Therapies

In some embodiments, the methods and compositions described herein is administered together with an additional agent or additional therapy (e.g., cancer treatment). In one embodiment, a mixture of one or more compounds or pharmaceutical compositions

may be administered with the combination described herein to a subject in need thereof. In yet another embodiment, one or more compounds or compositions (e.g., pharmaceutical compositions) may be administered with the combination described herein for the treatment or avoidance of various diseases, including, for example, cancer, diabetes, neurodegenerative diseases, cardiovascular disease, blood clotting, inflammation, flushing, obesity, aging, stress, etc. In various embodiments, combination therapies comprising a compound or pharmaceutical composition described herein may refer to (1) pharmaceutical compositions that comprise one or more compounds in combination with the combination described herein; and (2) co-administration of one or more compounds or pharmaceutical compositions described herein with the combination described herein, wherein the compound or pharmaceutical composition described herein have not been formulated in the same compositions. In some embodiments, the combinations described herein is administered with an additional treatment (e.g., an additional cancer treatment). In some embodiments, the additional treatment (e.g., an additional cancer treatment) can be administered simultaneously (e.g., at the same time), in the same or in separate compositions, or sequentially. Sequential administration refers to administration of one treatment before (e.g., immediately before, less than 5, 10, 15, 30, 45, 60 minutes; 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 48, 72, 96 or more hours; 4, 5, 6, 7, 8, 9 or more days; 1, 2, 3, 4, 5, 6, 7, 8 or more weeks before) administration of an additional, e.g., secondary, treatment (e.g., a compound or therapy). The order of administration of the first and secondary compound or therapy can also be reversed.


For example, the additional agent may be a FAK inhibitor. Potent inhibitors of the FAK protein tyrosine kinases may be adapted to therapeutic use as antiproliferative agents (e.g., anticancer), antitumor (e.g., effective against solid tumors), antiangiogenesis (e.g., stop or prevent proliferation of blood vessels) in mammals, particularly in humans. The compounds described herein, e.g., FAK inhibitors, may be useful in the prevention and treatment of a disease or disorder described herein (e.g., abnormal cell growth, e.g., cancer (e.g., a cancer described herein)).

An exemplary FAK inhibitor includes, but is not limited to, defactinib having the following structure:




or a pharmaceutically acceptable salt thereof. Defactinib is also known as VS-6063 (e.g., VS-6063 free base) or PF-04554878. VS-6063 and related compounds are also disclosed in, for example, U.S. Patent No. 7,928,109, the content of which is incorporated herein by reference. In some embodiments, VS-6063 can form a pharmaceutically acceptable salt (e.g., VS-6063 hydrochloride).

In some embodiments, the FAK inhibitor is VS-4718, having the following structure:




or a pharmaceutically acceptable salt thereof.

In some embodiments, the FAK inhibitor is TAE226, having the following structure:




or a pharmaceutically acceptable salt thereof.

In some embodiments, the FAK inhibitor is GSK2256098, having the following structure:




or a pharmaceutically acceptable salt thereof.

In some embodiments, the FAK inhibitor is PF-03814735, having the following structure:



or a pharmaceutically acceptable salt thereof.

In some embodiments, the FAK inhibitor is BI-4464, having the following structure:



or a pharmaceutically acceptable salt thereof.

In some embodiments, the FAK inhibitor is BI-853520 (IN10018; Boehringer
 5 Ingelheim). In some other embodiments, the FAK inhibitor is APG-2449 (Ascentage Pharma
 Group).

In some embodiments, the FAK inhibitor is selected from the group consisting of
 defactinib, TAE226, BI-853520, GSK2256098, PF-03814735, BI-4464, VS-4718, and APG-
 2449, or a pharmaceutically acceptable salt thereof. In some embodiments, the FAK inhibitor
 10 is defactinib or a pharmaceutically acceptable salt thereof.

In some embodiments, the FAK inhibitor is dosed at least once daily. For example, in
 some embodiments, the FAK inhibitor is dosed twice daily. In some embodiments, the FAK
 inhibitor is dosed once daily. For example, the daily dose of the FAK inhibitor may be about
 400 mg to about 800 mg (e.g., about 200 mg to about 400 mg twice daily).

In some embodiments, the FAK inhibitor is dosed at about 100 mg to about 1000 mg,
 e.g., about 100 mg to about 800 mg, about 100 mg to about 600 mg, about 100 mg to about
 400 mg, about 100 mg to about 200 mg, about 200 mg to about 1000 mg, about 400 mg to
 about 1000 mg, about 600 mg to about 1000 mg, about 800 mg to about 1000 mg, about 200
 mg to about 800 mg, about 200 mg to about 600 mg, about 200 mg to about 400 mg, about
 20 400 mg to about 800 mg, or about 400 mg to about 600 mg. In some embodiments, the FAK
 inhibitor is dosed at about 200 mg to about 400 mg. In some embodiments, the FAK
 inhibitor is dosed at about 100 mg. In some embodiments, the FAK inhibitor is dosed at about
 200 mg. In some embodiments, the FAK inhibitor is dosed at about 300 mg. In some
 embodiments, the FAK inhibitor is dosed at about 400 mg. In some embodiments, the FAK

inhibitor is dosed at about 500 mg. In some embodiments, the FAK inhibitor is dosed at about 600 mg. In some embodiments, the FAK inhibitor is administered orally.

In some embodiments, the MEK inhibitor (e.g., VS-6766 or a pharmaceutically acceptable salt thereof) is dosed cyclically for three weeks on and then one week off.

5 In some embodiments, the MEK inhibitor (e.g., VS-6766 or a pharmaceutically acceptable salt thereof) is administered in combination with an additional agent. In some embodiments, the additional agent is administered prior to the MEK inhibitor. In some embodiments, the additional agent is administered concurrently with the MEK inhibitor. In some embodiments, the additional agent is administered subsequent to the MEK inhibitor.

10 In some embodiments, the FAK inhibitor (e.g., defactinib or a pharmaceutically acceptable salt thereof) is dosed twice daily. In some embodiments, the FAK inhibitor (e.g., defactinib or a pharmaceutically acceptable salt thereof) is dosed once daily. In some embodiments, the FAK inhibitor (e.g., defactinib or a pharmaceutically acceptable salt thereof) is dosed at about 100 mg to about 1000 mg. In some embodiments, the FAK inhibitor (e.g., defactinib or a pharmaceutically acceptable salt thereof) is dosed at about 200 mg to about 400 mg (e.g., about 200 mg or about 400 mg). In some embodiments, the FAK inhibitor (e.g., defactinib or a pharmaceutically acceptable salt thereof) is dosed twice daily at about 200 mg to about 400 mg (e.g., about 200 mg or about 400 mg). In some embodiments, the FAK inhibitor (e.g., defactinib or a pharmaceutically acceptable salt thereof) is dosed daily at about 400 mg to about 800 mg (e.g., about 200 mg or about 400 mg twice daily).

15
20

In some embodiments, the MEK inhibitor (e.g., VS-6766 or a pharmaceutically acceptable salt thereof) and the FAK inhibitor (e.g., defactinib or a pharmaceutically acceptable salt thereof) are dosed cyclically (e.g., as a cycle comprising administering the MEK inhibitor and the FAK inhibitor for three weeks and then not administering the MEK inhibitor and the FAK inhibitor for one week).

25

In some embodiments, the MEK inhibitor (e.g., VS-6766 or a pharmaceutically acceptable salt thereof) and the FAK inhibitor (e.g., defactinib or a pharmaceutically acceptable salt thereof) are independently dosed cyclically. In some embodiments, the MEK inhibitor (e.g., VS-6766 or a pharmaceutically acceptable salt thereof) and the FAK inhibitor (e.g., defactinib or a pharmaceutically acceptable salt thereof) are simultaneously dosed cyclically.

30

In some embodiments, the MEK inhibitor (e.g., VS-6766 or a pharmaceutically acceptable salt thereof) is dosed at about 0.5 mg to about 10 mg and the FAK inhibitor (e.g.,

defactinib or a pharmaceutically acceptable salt thereof) is dosed at about 200 mg to about 400 mg. In some embodiments, the MEK inhibitor (e.g., VS-6766 or a pharmaceutically acceptable salt thereof) is dosed at about 4 mg twice a week and the FAK inhibitor (e.g., defactinib or a pharmaceutically acceptable salt thereof) is dosed at about 200 mg twice daily.

5 In some embodiments, the MEK inhibitor (e.g., VS-6766 or a pharmaceutically acceptable salt thereof) is dosed at about 3.2 mg twice a week and the FAK inhibitor (e.g., defactinib or a pharmaceutically acceptable salt thereof) is dosed at about 200 mg twice daily.

In some embodiments, the MEK inhibitor (e.g., VS-6766 or a pharmaceutically acceptable salt thereof) is dosed at about 4 mg twice a week and the FAK inhibitor (e.g., defactinib or a pharmaceutically acceptable salt thereof) is dosed at about 400 mg twice daily.

10 In some embodiments, the MEK inhibitor (e.g., VS-6766 or a pharmaceutically acceptable salt thereof) is dosed at about 3.2 mg twice a week and the FAK inhibitor (e.g., defactinib or a pharmaceutically acceptable salt thereof) is dosed at about 400 mg twice daily.

In some embodiments, the additional therapy is a cancer treatment. Exemplary cancer treatments include, for example: chemotherapy, targeted therapies such as antibody therapies, immunotherapy, and hormonal therapy. Examples of each of these treatments are provided below.

Chemotherapy

In some embodiments, a combination described herein is administered with a chemotherapy. Chemotherapy is the treatment of cancer with drugs that can destroy cancer cells. "Chemotherapy" usually refers to cytotoxic drugs which affect rapidly dividing cells in general, in contrast with targeted therapy. Chemotherapy drugs interfere with cell division in various possible ways, e.g., with the duplication of DNA or the separation of newly formed chromosomes. Most forms of chemotherapy target all rapidly dividing cells and are not specific for cancer cells, although some degree of specificity may come from the inability of many cancer cells to repair DNA damage, while normal cells generally can.

Examples of chemotherapeutic agents used in cancer therapy include, for example, antimetabolites (e.g., folic acid, purine, and pyrimidine derivatives) and alkylating agents (e.g., nitrogen mustards, nitrosoureas, platinum, alkyl sulfonates, hydrazines, triazenes, aziridines, spindle poison, cytotoxic agents, topoisomerase inhibitors and others). Exemplary agents include Aclarubicin, Actinomycin, Alitretinon, Altretamine, Aminopterin, Aminolevulinic acid, Amrubicin, Amsacrine, Anagrelide, Arsenic trioxide, Asparaginase, Atrasentan, Belotecan, Bexarotene, endamustine, Bleomycin, Bortezomib, Busulfan, Camptotnecin, Capecitabine, Carboplatin, Carboquone, Carmofur, Carmustine, Celecoxib,

Chlorambucil, Chlormethine, Cisplatin, Cladribine, Clofarabine, Crisantaspase, Cyclophosphamide, Cytarabine, Dacarbazine, Dactinomycin, Daunorubicin, Decitabine, Demecolcine, Docetaxel, Doxorubicin, Efavoxiral, Elesclomol, Elsamitrucin, Enocitabine, Epirubicin, Estramustine, Etoglucid, Etoposide, Floxuridine, Fludarabine, Fluorouracil (5FU), Fotemustine, Gemcitabine, Gliadel implants, Hydroxycarbamide, Hydroxyurea, idarubicin, Ifosfamide, Irinotecan, Irofulven, Ixabepilone, Larotaxel, Leucovorin, Liposomal doxorubicin, Liposomal daunorubicin, Lonidamine, Lomustine, Lucanthone, Mannosulfan, Masoprocol, Melphalan, Mercaptopurine, Mesna, Methotrexate, Methyl aminolevulinate, Mitobronitol, Mitoguanzone, Mitotane, Mitomycin, Mitoxantrone, Nedaplatin, Nimustine, Oblimersen, Omacetaxine, Ortataxel, Oxaliplatin, Paclitaxel, Pegaspargase, Pemetrexed, Pentostatin, Pirarubicin, Pixantrone, Plicamycin, Porfimer sodium, Prednimustine, Procarbazine, Raltitrexed, Ranimustine, Rubitecan, Sapacitabine, Semustine, Sitimagene ceradenovec, Strataplatin, Streptozocin, Talaporfm, Tegafur-uracil, Temoporfin, Temozolomide, Teniposide, Tesetaxel, Testolactone, Tetranitrate, Thiotepa, Tiazofurine, Tioguanine, Tipifarnib, Topotecan, Trabectedin, Triaziquone, Triethylenemelamine, Triplatin, Tretinoin, Treosulfan, Trofosfamide, Uramustine, Valrubicin, Verteporfin, Vinblastine, Vincristine, Vindesine, Vinflunine, Vinorelbine, Vorinostat, Zorubicin, and other cytostatic or cytotoxic agents described herein.

Because some drugs work better together than alone, two or more drugs are often given at the same time or sequentially. Often, two or more chemotherapy agents are used as combination chemotherapy. In some embodiments, the chemotherapy agents (including combination chemotherapy) can be used in combination with a combination described herein.

Targeted Therapy

In some embodiments, a combination described herein is administered with a targeted therapy. Targeted therapy constitutes the use of agents specific for the deregulated proteins of cancer cells. Small molecule targeted therapy drugs are generally inhibitors of enzymatic domains on mutated, overexpressed, or otherwise critical proteins within the cancer cell. Prominent examples are the tyrosine kinase inhibitors such as Axitinib, Bosutinib, Cediranib, desatinib, erlotinib, imatinib, gefitinib, lapatinib, Lestaurtinib, Nilotinib, Semaxanib, Sorafenib, Sunitinib, and Vandetanib, and also cyclin-dependent kinase inhibitors such as Alvocidib and Seliciclib. Monoclonal antibody therapy is another strategy in which the therapeutic agent is an antibody which specifically binds to a protein on the surface of the cancer cells. Examples include the anti-HER2/neu antibody trastuzumab (HERCEPTIN®)

typically used in breast cancer, and the anti-CD20 antibody rituximab and Tositumomab typically used in a variety of B-cell malignancies. Other exemplary antibodies include Ctuximab, Panitumumab, Trastuzumab, Alemtuzumab, Bevacizumab, Edrecolomab, and Gemtuzumab. Exemplary fusion proteins include Aflibercept and Denileukin diftitox. In
5 some embodiments, the targeted therapy can be used in combination with a combination described herein.

Targeted therapy can also involve small peptides as "homing devices" which can bind to cell surface receptors or affected extracellular matrix surrounding the tumor. Radionuclides which are attached to these peptides (e.g., RGDs) eventually kill the cancer cell if the nuclide
10 decay s in the vicinity of the cell. An example of such therapy includes BEXXAR®.

Immunotherapy

In some embodiments, a combination described herein is administered with an immunotherapy. Cancer immunotherapy refers to a diverse set of therapeutic strategies designed to induce the patient's own immune system to fight the tumor.

15 Contemporary methods for generating an immune response against tumors include intravesicular BCG immunotherapy for superficial bladder cancer, and use of interferons and other cytokines to induce an immune response in subjects with renal cell carcinoma and melanoma. Allogeneic hematopoietic stem cell transplantation can be considered a form of immunotherapy, since the donor's immune cells will often attack the tumor in a graft- versus-
20 tumor effect. In some embodiments, the immunotherapy agents can be used in combination with a combination as described herein.

Hormonal Therapy

In some embodiments, a combination described is administered with a hormonal therapy. The growth of some cancers can be inhibited by providing or blocking certain
25 hormones. Common examples of hormone-sensitive tumors include certain types of breast and prostate cancers. Removing or blocking estrogen or testosterone is often an important additional treatment. In certain cancers, administration of hormone agonists, such as progestogens may be therapeutically beneficial. In some embodiments, the hormonal therapy agents can be used in combination with a combination described herein.

Radiation Therapy

30 The combinations described herein can be used in combination with directed energy or particle, or radioisotope treatments, e.g., radiation therapies, e.g., radiation oncology, for the treatment of proliferative disease, e.g., cancer, e.g., cancer associated with cancer stem cells. The combinations described herein may be administered to a subject simultaneously or

sequentially along with the directed energy or particle, or radioisotope treatments. For example, the combinations described herein may be administered before, during, or after the directed energy or particle, or radioisotope treatment, or a combination thereof. The directed energy or particle therapy may comprise total body irradiation, local body irradiation, or point irradiation. The directed energy or particle may originate from an accelerator, 5 synchrotron, nuclear reaction, vacuum tube, laser, or from a radioisotope. The therapy may comprise external beam radiation therapy, teletherapy, brachy therapy, sealed source radiation therapy, systemic radioisotope therapy, or unsealed source radiotherapy. The therapy may comprise ingestion of, or placement in proximity to, a radioisotope, e.g., 10 radioactive iodine, cobalt, cesium, potassium, bromine, fluorine, carbon. External beam radiation may comprise exposure to directed alpha particles, electrons (e.g., beta particles), protons, neutrons, positrons, or photons (e.g., radiowave, millimeter wave, microwave, infrared, visible, ultraviolet, X-ray, or gamma-ray photons). The radiation may be directed at any portion of the subject in need of treatment.

15 *Surgery*

The combinations described herein can be used in combination with surgery, e.g., surgical exploration, intervention, biopsy, for the treatment of proliferative disease, e.g., cancer, e.g., cancer associated with cancer stem cells. The combinations described herein may be administered to a subject simultaneously or sequentially along with the surgery. For 20 example, the combinations described herein may be administered before (preoperative), during, or after (post-operative) the surgery, or a combination thereof. The surgery may be a biopsy during which one or more cells are collected for further analysis. The biopsy may be accomplished, for example, with a scalpel, a needle, a catheter, an endoscope, a spatula, or scissors. The biopsy may be an excisional biopsy, an incisional biopsy, a core biopsy, or a 25 needle biopsy, e.g., a needle aspiration biopsy. The surgery may involve the removal of localized tissues suspected to be or identified as being cancerous. For example, the procedure may involve the removal of a cancerous lesion, lump, polyp, or mole. The procedure may involve the removal of larger amounts of tissue, such as breast, bone, skin, fat, or muscle. The procedure may involve removal of part of, or the entirety of, an organ or node, for example, 30 lung, throat, tongue, bladder, cervix, ovary, testicle, lymph node, liver, pancreas, brain, eye, kidney, gallbladder, stomach, colon, rectum, or intestine. In one embodiment, the cancer is breast cancer, e.g., triple negative breast cancer, and the surgery is a mastectomy or lumpectomy.

Anti-Inflammatory Agents

A combination described herein can be administered with an anti-inflammatory agent. Anti-inflammatory agents can include, but are not limited to, non-steroidal anti-inflammatory agents (e.g., Salicylates (Aspirin (acetylsalicylic acid), Diflunisal, Salsalate), Propionic acid derivatives (Ibuprofen, Naproxen, Fenoprofen, Ketoprofen, Flurbiprofen, Oxaprozin, Loxoprofen), Acetic acid derivatives (Indomethacin, Sulindac, Etodolac, Ketorolac, Diclofenac, Nabumetone), Enolic acid (Oxicam) derivatives (Piroxicam, Meloxicam, Tenoxicam, Droxicam, Lomoxicam, Isoxicam), Fenamic acid derivatives (Fenamates)(Mefenamic acid, Meclofenamic acid, Flufenamic acid. Tolfenamic acid). Selective COX -2 inhibitors (Coxibs) (Ceiecoxib), Sulphonanilides (Nimesulide). Steroids (e.g. Hydrocortisone (Cortisol), Cortisone acetate, Prednisone, Prednisolone, Methylprednisolone, Dexamethasone, Betamethasone, Triamcinolone, Beclometasone, Fludrocortisone acetate, Deoxycorticosterone acetate, Aldosterone).

Analgesic Agents

Analgesics can include but are not limited to, opiates (e.g. morphine, codeine, oxycodone, hydrocodone, dihydromorphine, pethidine, buprenorphine, tramadol, venlafaxine), paracetamol and Nonsteroidal anti-inflammatory agents (e.g., Salicylates (Aspirin (acetylsalicylic acid), Diflunisal, Salsalate), Propionic acid derivatives (Ibuprofen, Naproxen, Fenoprofen, Ketoprofen, Flurbiprofen, Oxaprozin, Loxoprofen), Acetic acid derivatives (Indomethacin, Sulindac, Etodolac, Ketorolac, Diclofenac, Nabumetone), Enolic acid (Oxicam) derivatives (Piroxicam, Meloxicam, Tenoxicam, Droxicam, Lomoxicam, Isoxicam), Fenamic acid derivatives (Fenamates)(Mefenamic acid, Meclofenamic acid, Flufenamic acid. Tolfenamic acid). Selective COX-2 inhibitors (Coxibs) (Ceiecoxib), Sulphonanilides (Nimesulide).

Antiemetic Agents

A combination described herein can be administered with an antiemetic agent. Antiemetic agents can include, but are not limited to, 5-HT₃ receptor antagonists (Dolasetron (Anzemet), Granisetron (Kytril, Sancuso), Ondansetron (Zofran), Tropisetron (Navoban), Palonosetron (Aloxi), Mirtazapine (Remeron)), Dopamine antagonists (Domperidone, Olanzapine, Droperidol, Haloperidol, Chlorpromazine, Promethazine, Prochlorperazine, Metoclopramide (Reglan), Alizapride, Prochlorperazine (Compazine, Stemizine, Buccastem, Stemetil, Phenotil), NK₁ receptor antagonist (Aprepitant (Emend), Antihistamines (Cyclizine, Diphenhydramine (Benadryl), Dimenhydrinate (Gravol, Dramamine), Meclozine (Bonine,

Antivert), Promethazine (Pentazine, Phenergan, Promacot), Hydroxyzine), benzodiazapines (Lorazepam, Midazolam), Anticholinergics (hyoscine), steroids (Dexamethasone).

The phrase, "in combination with," and the terms "co-administration," "co-administering," or "co-providing", as used herein in the context of the administration of a
5 compound described herein or a therapy described herein, means that two (or more) different compounds or therapies are delivered to the subject during the course of the subject's affliction with the disease or disorder (e.g., a disease or disorder as described herein, e.g., cancer), e.g., two (or more) different compounds or therapies are delivered to the subject after
10 the subject has been diagnosed with the disease or disorder (e.g., a disease or disorder as described herein, e.g., cancer) and before the disease or disorder has been cured or eliminated or treatment has ceased for other reasons.

In some embodiments, the delivery of one compound or therapy is still occurring when the delivery of the second begins, so that there is overlap in terms of administration. This is sometimes referred to herein as "simultaneous" or "concurrent delivery." In other
15 embodiments, the delivery of one compound or therapy ends before the delivery of the other compound or therapy begins. In some embodiments of either case, the treatment (e.g., administration of compound, composition, or therapy) is more effective because of combined administration. For example, the second compound or therapy is more effective, e.g., an equivalent effect is seen with less of the second compound or therapy, or the second
20 compound or therapy reduces symptoms to a greater extent, than would be seen if the second compound or therapy were administered in the absence of the first compound or therapy, or the analogous situation is seen with the first compound or therapy. In some embodiments, delivery is such that the reduction in a symptom, or other parameter related to the disorder is greater than what would be observed with one compound or therapy delivered in the absence
25 of the other. The effect of the two compounds or therapies can be partially additive, wholly additive, or great than additive (e.g., synergistic). The delivery can be such that the first compound or therapy delivered is still detectable when the second is delivered.

In some embodiments, the first compound or therapy and second compound or therapy can be administered simultaneously (e.g., at the same time), in the same or in
30 separate compositions, or sequentially. Sequential administration refers to administration of one compound or therapy before (e.g., immediately before, less than 5, 10, 15, 30, 45, 60 minutes; 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 48, 72, 96 or more hours; 4, 5, 6, 7, 8, 9 or more days; 1, 2, 3, 4, 5, 6, 7, 8 or more weeks before) administration of an additional, e.g.,

secondary, compound or therapy. The order of administration of the first and secondary compound or therapy can also be reversed.

The combinations described herein can be a first line treatment for abnormal cell growth, e.g., cancer, i.e., it is used in a patient who has not been previously administered another drug intended to treat the cancer; a second line treatment for the cancer, i.e., it is used in a subject in need thereof who has been previously administered another drug intended to treat the cancer; a third or fourth treatment for the cancer, i.e., it is used in a subject who has been previously administered two or three other drugs intended to treat the cancer.

10 *Oral Dosage Forms and Formulations*

The compounds of this invention may be administered orally. In some embodiments the composition (e.g., pharmaceutical composition) is orally administered in any orally acceptable dosage form including, but not limited to, liqui-gel tablets or capsules, syrups, emulsions and aqueous suspensions. Liqui-gels may include gelatins, plasticisers, and/or opacifiers, as needed to achieve a suitable consistency and may be coated with enteric coatings that are approved for use, e.g., shellacs. Additional thickening agents, for example gums, e.g., xanthum gum, starches, e.g., corn starch, or glutens may be added to achieve a desired consistency of the composition (e.g., pharmaceutical composition) when used as an oral dosage. If desired, certain sweetening and/or flavoring and/or coloring agents may be added.

In some embodiments, the subject is administered the composition (e.g., pharmaceutical composition) in a form suitable for oral administration such as a tablet, capsule, pill, powder, sustained release formulations, solution, and suspension. The composition (e.g., pharmaceutical composition) may be in unit dosage forms suitable for single administration of precise dosages. Pharmaceutical compositions may comprise, in addition to a compound as described herein a pharmaceutically acceptable carrier, and may optionally further comprise one or more pharmaceutically acceptable excipients, such as, for example, stabilizers, diluents, binders, and lubricants. In addition, the tablet may include other medicinal or pharmaceutical agents, carriers, and or adjuvants. Exemplary pharmaceutical compositions include compressed tablets (e.g., directly compressed tablets).

Tablets are also provided comprising the active or therapeutic ingredient (e.g., compound as described herein). In addition to the active or therapeutic ingredients, tablets may contain a number of inert materials such as carriers. Pharmaceutically acceptable carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable

or synthetic origin, such as peanut oil, sesame oil and the like. Saline solutions and aqueous dextrose can also be employed as liquid earners. Oral dosage forms for use in accordance with the present invention thus may be formulated in conventional manner using one or more pharmaceutically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active ingredients into preparations which, can be used pharmaceutically. Excipients can impart good powder flow and compression characteristics to the material being compressed. Examples of excipients are described, for example, in the Handbook of Pharmaceutical Excipients (5th edition), Edited by Raymond C Rowe, Paul J. Sheskey, and Sian C. Owen; Publisher: Pharmaceutical Press.

For oral administration, the active ingredients, e.g., the compound as described herein can be formulated readily by combining the active ingredients with pharmaceutically acceptable carriers well known in the art. Such carriers enable the active ingredients of the invention to be formulated as tablets, pills, capsules, liquids, gels, syrups, slurries, powders or granules, suspensions or solutions in water or non-aqueous media, and the like, for oral ingestion by a subject. Pharmacological preparations for oral use can be made using a solid excipient, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries if desired, to obtain, for example, tablets. Suitable excipients such as diluents, binders or disintegrants may be desirable.

The dosage may vary depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See e.g., Fingl, et al., 1975, in 'The Pharmacological Basis of Therapeutics'). Lower or higher doses than those recited above may be required. Specific dosage and treatment regimens for any particular subject will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health status, sex, diet, time of administration, rate of excretion, drug combination, the severity and course of the disease, condition or symptoms, the subject's disposition to the disease, condition or symptoms, and the judgment of the treating physician. A course of therapy can comprise one or more separate administrations of a compound as described herein. A course of therapy can comprise one or more cycles of a compound as described herein.

In some embodiments, a cycle, as used herein in the context of a cycle of administration of a drug, refers to a period of time for which a drug is administered to a patient. For example, if a drug is administered for a cycle of 21 days, the periodic administration, e.g., daily or twice daily, is given for 21 days. A drug can be administered for

more than one cycle. Rest periods may be interposed between cycles. A rest cycle may be 1, 2, 4, 6, 8, 10, 12, 16, 20, 24 hours, 1, 2, 3, 4, 5, 6, 7 days, or 1, 2, 3, 4 or more weeks in length.

Oral dosage forms may, if desired, be presented in a pack or dispenser device, such as an FDA approved kit, which may contain one or more unit dosage forms containing the active ingredient. The pack may, for example, comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. The pack or dispenser may also be accompanied by a notice associated with the container in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the compositions or human or veterinary administration. Such notice, for example, may be of labeling approved by the U.S. Food and Drug Administration for prescription drugs or of an approved product insert.

15 *Screening*

The methods provided herein also encompass methods for screening or identifying subjects having a cancer suitable for treatment with a MEK inhibitor (e.g., a dual RAF/MEK inhibitor) (alternatively, a pan-RAF inhibitor) alone or in combination with an additional agent (e.g., a FAK inhibitor). For example, the methods contemplate identifying a subject who is likely to be responsive to a treatment of a cancer described herein. Also provided are methods for optimizing therapeutic efficacy for treatment of a subject having a cancer, wherein the treatment comprises administering a MEK inhibitor (e.g., a dual RAF/MEK inhibitor) or a pharmaceutically acceptable salt thereof (alternatively, a pan-RAF inhibitor) alone or in combination with an additional agent (e.g., a FAK inhibitor).

25 In an aspect, provided herein is a method of detecting presence of a KRAS gene mutation associated with a subject having a cancer, the method comprising:

- (a) obtaining a biological sample from the subject; and
- (b) performing an assay that screen for mutation in the sample.

In an aspect, provided herein is a method of identifying a subject having a cancer with a KRAS gene mutation, the method comprising:

- (a) obtaining a biological sample from the subject; and
- (b) performing an assay that screen for mutation in the sample.

In some embodiments, the KRAS gene mutation is G12A, G12C, G12D, G12R, G12S, G12V or G13D.

In some embodiments, the methods further comprise administering to the subject identified as having a cancer with a KRAS mutation (e.g., KRAS G12X mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C)) an effective amount of a MEK inhibitor described herein (e.g., a dual RAF/MEK inhibitor) or a pharmaceutically acceptable salt thereof alone or in combination with an additional agent (e.g., a FAK inhibitor).

In alternative embodiments, the methods may further comprise administering to the subject identified as having a cancer with a KRAS mutation (e.g., KRAS G12X mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C)) an effective amount of a pan-RAF inhibitor alone or in combination with an additional agent (e.g., a FAK inhibitor).

Samples include, but are not limited to, tissue samples (e.g., tumor tissue samples), primary or cultured cells or cell lines, cell supernatants, cell lysates, platelets, serum, plasma, vitreous fluid, lymph fluid, synovial fluid, follicular fluid, seminal fluid, amniotic fluid, milk, whole blood, blood-derived cells, urine, cerebro-spinal fluid, saliva, sputum, tears, perspiration, mucus, tumor lysates, and tissue culture medium, tissue extracts such as homogenized tissue, tumor tissue, cellular extracts, and combinations thereof. In some embodiments, the sample is serum, blood, urine, or plasma.

Identification of the particular mutational status of the KRAS gene in a sample obtained from the individual may be performed by any of a number of methods well known to one of skill in the art. For example, identification of the mutation can be accomplished by cloning of the KRAS gene, or portion thereof, and sequencing it using techniques well known in the art. Alternatively, the gene sequences can be amplified from genomic DNA, e.g. using PCR, and the product sequenced. In some embodiments, the assay comprises sequencing. In some embodiments, the assay comprises polymerase chain reaction (PCR). Exemplary assay includes, but is not limited to, nucleic acid sequencing (dideoxy and pyrosequencing), real-time PCR with melt-curve analysis, and allele-specific PCR with various modes used to distinguish mutant from wild-type sequences. Assay may also include quantitatively or semi-quantitatively determining the amount of the mutation in cell free DNA (cfDNA) in the sample.

EXAMPLES

In order that the invention described herein may be more fully understood, the following examples are set forth. The examples described in this application are offered to

illustrate the pharmaceutical compositions and methods provided herein and are not to be construed in any way as limiting their scope.

Example 1. Clinical activity in discrete KRAS codon 12 variants with defactinib and VS-6766

5 In this study, VS-6766 was dosed twice a week, and defactinib was dosed twice a day (BID) for 3 weeks of a 4 week cycle (i.e., both drugs administered for 3 weeks on and 1 week off; 1 cycle = 4 weeks). VS-6766 was dosed at 3.2 mg or 4.0 mg per dose; defactinib was dosed at 200 mg or 400 mg per dose. VS-6766 and defactinib were orally administered. Table 1 below shows the clinical activity of defactinib and VS-6766 in KRAS mutated
10 ovarian and lung cancers.

Table 1.

Tumor Type		G12V	G12D	G12A	G12C
Ovarian	# patients	3	3	1	0
	PR	2 (67%)	2 (67%)	1 (100%)	
	Disease Control	3 (100%)	3 (100%)	1 (100%)	
	≥6 months time on therapy	2 (67%)	2 (67%)	1 (100%)	
Lung	# patients	1	5	1	2
	PR	1 (100%)	1 (20%)*	0 (0%)	0 (0%)
	Disease Control	1 (100%)	4 (80%)	1 (100%)	2 (100%)
	≥6 months time on therapy	1 (100%)	4 (80%)	1 (100%)	2 (100%)

* 22% reduction and still on treatment

Example 2. Effect of VS-6766 and defactinib in KRAS G12V tumors

15 The effect of monotherapy of VS-6766 (Martinez-Garcia, M. et al, *Clin. Cancer Res.* 2012) was compared to the combination therapy of VS-6766 and defactinib in KRAS G12V tumors. The combination of VS-6766 and defactinib were administered as described in Example 1. **FIG. 1** shows the best response by Response Evaluation Criteria in Solid Tumors (RECIST) in KRAS G12V NSCLC for the monotherapy of VS-6766 and
20 combination therapy of VS-6766 and defactinib in KRAS G12V NSCLC. All Partial Responses (PRs) were confirmed with subsequent scan per RECIST. **FIG. 2** shows the time on treatment for KRAS G12V NSCLC. The combination therapy of VS-6766 and defactinib has a 57% Overall Response Rate (ORR) in KRAS G12V NSCLC. **FIG. 3** and **FIG. 4** show the best response by RECIST in KRAS G12V tumors (endometrial, NSCLC, and ovarian)

and time on treatment, respectively. The data shows that the combination therapy of VS-6766 and defactinib has a 58% ORR in KRAS G12V tumors.

Equivalents and Scope

5 In the claims articles such as “a,” “an,” and “the” may mean one or more than one unless indicated to the contrary or otherwise evident from the context. Claims or descriptions that include “or” between one or more members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the
10 context. The invention includes embodiments in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process. The invention includes embodiments in which more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process.

Furthermore, the invention encompasses all variations, combinations, and
15 permutations in which one or more limitations, elements, clauses, and descriptive terms from one or more of the listed claims is introduced into another claim. For example, any claim that is dependent on another claim can be modified to include one or more limitations found in any other claim that is dependent on the same base claim. Where elements are presented as lists, e.g., in Markush group format, each subgroup of the elements is also disclosed, and any
20 element(s) can be removed from the group. It should it be understood that, in general, where the invention, or aspects of the invention, is/are referred to as comprising particular elements and/or features, certain embodiments of the invention or aspects of the invention consist, or consist essentially of, such elements and/or features. For purposes of simplicity, those embodiments have not been specifically set forth *in haec verba* herein. It is also noted that
25 the terms “comprising” and “containing” are intended to be open and permits the inclusion of additional elements or steps. Where ranges are given, endpoints are included. Furthermore, unless otherwise indicated or otherwise evident from the context and understanding of one of ordinary skill in the art, values that are expressed as ranges can assume any specific value or sub-range within the stated ranges in different embodiments of the invention, to the tenth of
30 the unit of the lower limit of the range, unless the context clearly dictates otherwise.

This application refers to various issued patents, published patent applications, journal articles, and other publications, all of which are incorporated herein by reference. If there is a conflict between any of the incorporated references and the instant specification, the

specification shall control. In addition, any particular embodiment of the present invention that falls within the prior art may be explicitly excluded from any one or more of the claims. Because such embodiments are deemed to be known to one of ordinary skill in the art, they may be excluded even if the exclusion is not set forth explicitly herein. Any particular
5 embodiment of the invention can be excluded from any claim, for any reason, whether or not related to the existence of prior art.

Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation many equivalents to the specific embodiments described herein. The scope of the present embodiments described herein is not intended to be limited to the above
10 Description, but rather is as set forth in the appended claims. Those of ordinary skill in the art will appreciate that various changes and modifications to this description may be made without departing from the spirit or scope of the present invention, as defined in the following claims.

CLAIMS

We claim:

- 5 1. A method of treating a cancer in a subject identified as having a KRAS G12V mutation, the method comprising administering to the subject an effective amount of a MEK inhibitor, thereby treating the subject.
2. A method of treating a cancer in a subject identified as having a KRAS G12D
10 inhibitor, thereby treating the subject.
3. A method of treating a cancer characterized as having a KRAS G12V mutation in a subject in need thereof, the method comprising administering to the subject an effective amount of a MEK inhibitor, thereby treating the subject.
- 15 4. A method of treating a cancer characterized as having a KRAS G12D mutation in a subject in need thereof, the method comprising administering to the subject an effective amount of a MEK inhibitor, thereby treating the subject.
5. A method of treating a cancer in a subject in need thereof, comprising administering
20 to the subject an effective amount of a MEK inhibitor, wherein the subject has previously been identified as having a KRAS G12V mutation.
6. A method of treating a cancer in a subject in need thereof, comprising administering
25 to the subject an effective amount of a MEK inhibitor, wherein the subject has previously been identified as having a KRAS G12D mutation.
7. A method of treating a cancer in a subject in need thereof, comprising selecting a subject with cancer having a KRAS G12V mutation in a tumor of the subject; and treating the subject with an effective amount of a MEK inhibitor.

30

8. A method of treating cancer in a subject in need thereof, comprising selecting a subject with cancer having a KRAS G12D mutation in a tumor of the subject; and treating the subject with an effective amount of a MEK inhibitor.
- 5 9. The method of any one of claims 1-8, wherein the MEK inhibitor is selected from the group consisting of trametinib, cobimetinib, binimetinib, selumetinib, PD-325901, CI-1040, VS-6766, MEK162, AZD8330, GDC-0623, refametinib, pimasertib, WX-554, HL-085, CH4987655, TAK-733, CInQ-03, G-573, PD184161, PD318088, PD98059, RO5068760, U0126, and SL327, or a pharmaceutically acceptable salt thereof.
- 10 10. The method of any one of claims 1-9, wherein the MEK inhibitor is a dual RAF/MEK inhibitor.
11. The method of any one of claims 1-10, wherein the MEK inhibitor is VS-6766 or a pharmaceutically acceptable salt thereof.
12. The method of any one of claims 1-11, wherein the MEK inhibitor is dosed once a
15 week.
13. The method of any one of claims 1-11, wherein the MEK inhibitor is dosed twice a week.
14. The method of any one of claims 1-11, wherein the MEK inhibitor is dosed once daily.
- 20 15. The method of any one of claims 1-11, wherein the MEK inhibitor is dosed twice daily.
16. The method of any one of claims 1-15, wherein the MEK inhibitor is dosed for at least three weeks.
17. The method of any one of claims 1-16, wherein the MEK inhibitor is dosed as a cycle,
25 wherein the cycle comprises administering the MEK inhibitor for three weeks and then not administering the MEK inhibitor for one week.
18. The method of any one of claims 1-17, wherein the MEK inhibitor is dosed at about 0.1 mg to about 100 mg.

19. The method of any one of claims 1-18, wherein the MEK inhibitor is dosed at about 0.5 mg to about 10 mg.
20. The method of any one of claims 1-19, wherein the MEK inhibitor is dosed at about 4 mg.
- 5 21. The method of any one of claims 1-19, wherein the MEK inhibitor is dosed at about 3.2 mg.
22. The method of any one of claims 1-21, wherein the MEK inhibitor is administered orally.
23. The method of any one of claims 1-22, further comprising administering to the subject
10 an additional agent.
24. The method of claim 23, wherein the additional agent is administered prior to the MEK inhibitor.
25. The method of claim 23, wherein the additional agent is administered concurrently with the MEK inhibitor.
- 15 26. The method of claim 23, wherein the additional agent is administered subsequent to the MEK inhibitor.
27. The method of any one of claims 23-26, wherein the additional agent is a FAK inhibitor.
28. The method of claim 27, wherein the FAK inhibitor is selected from the group
20 consisting of defactinib, TAE226, BI-853520 (IN10018), GSK2256098, PF-03814735, BI-4464, VS-4718, and APG-2449, or a pharmaceutically acceptable salt thereof.
29. The method of claim 27 or 28, wherein the FAK inhibitor is defactinib or a pharmaceutically acceptable salt thereof.
30. The method of any one of claims 27-29, wherein the FAK inhibitor is dosed twice
25 daily.
31. The method of any one of claims 27-29, wherein the FAK inhibitor is dosed once daily.

32. The method of any one of claims 27-31, wherein the FAK inhibitor is dosed at about 100 mg to about 1000 mg.
33. The method of any one of claims 27-32, wherein the FAK inhibitor is dosed at about 200 mg to about 400 mg.
- 5 34. The method of any one of claims 27-33, wherein the FAK inhibitor is dosed at about 200 mg.
35. The method of any one of claims 27-33, wherein the FAK inhibitor is dosed at about 400 mg.
- 10 36. The method of any one of claims 27-35, wherein the FAK inhibitor is administered orally.
37. The method of any one of claims 1-36, wherein the cancer is ovarian cancer, non-small cell lung cancer (e.g., NSCLC adenocarcinoma)), uterine endometrioid carcinoma, pancreatic adenocarcinoma, colorectal adenocarcinoma, or lung adenocarcinoma.
- 15 38. The method of any one of claims 1-37, wherein the cancer is non-small cell lung cancer.
39. A method of treating a cancer in a subject identified as having a KRAS G12V mutation, the method comprising administering to the subject an effective amount of a pan-RAF inhibitor, thereby treating the subject.
- 20 40. A method of treating a cancer in a subject identified as having a KRAS G12D mutation, the method comprising administering to the subject an effective amount of a pan-RAF inhibitor, thereby treating the subject.




FIG. 1




FIG. 2

■ Endometrial (50%; N=2) ■ NSCLC (57% ORR; N=7) □ Ovc (66% ORR; N=3)




FIG. 3

4/4




FIG. 4

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2021/029435

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

- 1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

- 2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

- 3. Claims Nos.: 10-38
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

- 1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
- 2. As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
- 3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

- 4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2021/029435

A. CLASSIFICATION OF SUBJECT MATTER IPC(8) - A61P 35/00; C12Q 1/6886 (2021.01) CPC - A61P 35/00; C12Q 1/6886; C12Q 2600/106; C12Q 2600/156 (2021.05)		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) see Search History document		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched see Search History document		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) see Search History document		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2012/0214828 A1 (HATZIVASSILIOU et al) 23 August 2012 (23.08.2012) entire document	1-9
X	WO 2019/051296 A1 (GENENTECH, INC. et al) 14 March 2019 (14.03.2019) entire document	39, 40
A	US 2013/0217710 A1 (ALVES-AIVADO et al) 22 August 2013 (22.08.2013) entire document	1-9, 39, 40
A	US 2018/0289683 A1 (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA et al) 11 October 2018 (11.10.2018) entire document	1-9, 39, 40
A	MOLNAR et al., Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells, BMC Cancer, 08 May 2018 (08.05.2018), Vol. 18, Art. No: 542, Pgs. 1-11. entire document	1-9, 39, 40
A	US 2014/0194442 A1 (SOLCA et al) 10 July 2014 (10.07.2014) entire document	1-9, 39, 40
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "D" document cited by the applicant in the international application "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 13 July 2021		Date of mailing of the international search report AUG 03 2021
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US, Commissioner for Patents P.O. Box 1450, Alexandria, VA 22313-1450 Facsimile No. 571-273-8300		Authorized officer Harry Kim Telephone No. PCT Helpdesk: 571-272-4300